PTGER4 and lung cancer: Several early studies demonstrated that small molecule EP4 antagonists (AH23848; ONO-AE3-208) or EP4 gene silencing reduced metastatic potential in vivo in preclinical models of breast, prostate, colon, and lung cancer (Ma et al., 2006; Yang et al., 2006; Xu et al., 2018).